These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31460584)

  • 1. N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL.
    Oliveira CP; Cotrim HP; Stefano JT; Siqueira ACG; Salgado ALA; Parise ER
    Arq Gastroenterol; 2019 Aug; 56(2):184-190. PubMed ID: 31460584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-administration of metformin and N-acetylcysteine with dietary control improves the biochemical and histological manifestations in rats with non-alcoholic fatty liver.
    El-Lakkany NM; Seif El-Din SH; Sabra AA; Hammam OA; Ebeid FA
    Res Pharm Sci; 2016 Oct; 11(5):374-382. PubMed ID: 27920819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis.
    de Oliveira CP; Stefano JT; de Siqueira ER; Silva LS; de Campos Mazo DF; Lima VM; Furuya CK; Mello ES; Souza FG; Rabello F; Santos TE; Nogueira MA; Caldwell SH; Alves VA; Carrilho FJ
    Hepatol Res; 2008; 38(2):159-65. PubMed ID: 18197877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.
    Leuschner UF; Lindenthal B; Herrmann G; Arnold JC; Rössle M; Cordes HJ; Zeuzem S; Hein J; Berg T;
    Hepatology; 2010 Aug; 52(2):472-9. PubMed ID: 20683947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
    Ali MH; Messiha BA; Abdel-Latif HA
    Pharm Biol; 2016 Jul; 54(7):1198-208. PubMed ID: 26134756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
    Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
    Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.
    Parikh P; Ingle M; Patel J; Bhate P; Pandey V; Sawant P
    Saudi J Gastroenterol; 2016; 22(3):192-7. PubMed ID: 27184636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
    Ratziu V; de Ledinghen V; Oberti F; Mathurin P; Wartelle-Bladou C; Renou C; Sogni P; Maynard M; Larrey D; Serfaty L; Bonnefont-Rousselot D; Bastard JP; Rivière M; Spénard J;
    J Hepatol; 2011 May; 54(5):1011-9. PubMed ID: 21145828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways.
    Ahmed LA; Salem MB; Seif El-Din SH; El-Lakkany NM; Ahmed HO; Nasr SM; Hammam OA; Botros SS; Saleh S
    Eur J Pharmacol; 2020 Nov; 887():173461. PubMed ID: 32758573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial.
    Alam S; Kabir J; Mustafa G; Gupta U; Hasan SK; Alam AK
    Saudi J Gastroenterol; 2016; 22(1):69-76. PubMed ID: 26831610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A; Akhter A
    Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial].
    Lee SH; Cheon GJ; Kim HS; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS
    Korean J Gastroenterol; 2014 Jul; 64(1):31-9. PubMed ID: 25073669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
    Ozel Coskun BD; Yucesoy M; Gursoy S; Baskol M; Yurci A; Yagbasan A; Doğan S; Baskol G
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):142-9. PubMed ID: 25533429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
    Torres DM; Jones FJ; Shaw JC; Williams CD; Ward JA; Harrison SA
    Hepatology; 2011 Nov; 54(5):1631-9. PubMed ID: 21748770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
    Fouda A; Abdelaziz AE; Hussien M; Ali AA; Abdelkawy KS; Elbarbry F
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7449-7459. PubMed ID: 34919247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
    Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
    Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.